Back to UBS Group AG UBS Group AG

VTGNVTGN
13 quarters

Position history for UBS Group AGUBS Group AG's holdings in VISTAGEN THERAPEUTICS INC

Yes. Ubs holds 57,830 shares of VTGN (Vistagen Therapeutics), worth $13,070, as of its Q2 2026 13F filing. It reduced the position by 20,906 shares (-26.6%) from Q1 2026. Ubs has held VTGN in every 13F on record since Q2 2023, 13 quarterly filings.

Current Value

$13,070

Current Shares

57,830

Total Value Change

+$12,851

Total Shares Change

+57,713

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
57,830
-26.6%
$13,0700.0%$0.23
0
2026-Q1
Increased
78,736
+51.4%
$45,0370.0%$0.57
19
2025-Q4
Increased
51,993
+102.6%
$34,4190.0%$0.66
22
2025-Q3
Increased
25,667
+12.5%
$91,1180.0%$3.55
17
2025-Q2
Decreased
22,813
-11.5%
$45,6260.0%$2.00
0
2025-Q1
Decreased
25,779
-80.5%
$64,4480.0%$2.50
0
2024-Q4
Increased
132,314
+1207.3%
$390,3260.0%$2.95
38
2024-Q3
Decreased
10,121
-47.5%
$30,4640.0%$3.01
0
2024-Q2
Increased
19,266
+306.8%
$67,0460.0%$3.48
23
2024-Q1
Increased
4,736
+3947.9%
$25,0060.0%$5.28
21
2023-Q4
Decreased
117
-92.2%
$6010.0%$5.14
0
2023-Q3
Increased
1,498
+1180.3%
$7,8490.0%$5.24
18
2023-Q2
New
117
-
$2190.0%$1.87
17

Other major holders of VTGN: Janus Henderson Group Ltd., VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used